Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Cidara Therapeutics Inc

CDTX
Current price
11.81 USD -0.83 USD (-6.57%)
Last closed 12.64 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 53 782 560 USD
Yield for 12 month +1 014.15 %
1Y
3Y
5Y
10Y
15Y
CDTX
21.11.2021 - 28.11.2021

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

81.25 USD

P/E ratio

Dividend Yield

Current Year

+63 905 000 USD

Last Year

+64 288 000 USD

Current Quarter

+17 583 000 USD

Last Quarter

+17 583 000 USD

Current Year

+62 382 000 USD

Last Year

+64 288 000 USD

Current Quarter

+16 447 000 USD

Last Quarter

+16 447 000 USD

Key Figures CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -37 839 000 USD
Operating Margin TTM -126.33 %
PE Ratio
Return On Assets TTM -35.29 %
PEG Ratio
Return On Equity TTM -800.93 %
Wall Street Target Price 81.25 USD
Revenue TTM 46 261 000 USD
Book Value -3.9 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -67.6 %
Dividend Yield
Gross Profit TTM -11 232 000 USD
Earnings per share -8.08 USD
Diluted Eps TTM -8.08 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin -78.4 %

Dividend Analytics CDTX

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:20
Payout Ratio
Last Split Date 24.04.2024
Dividend Date

Stock Valuation CDTX

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 5.7504
Enterprise Value Revenue 0.5145
Price Sales TTM 1.2982
Enterprise Value EBITDA -0.9542
Price Book MRQ 9.1318

Financials CDTX

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CDTX

For 52 weeks

10 USD 24.4 USD
50 Day MA 12.28 USD
Shares Short Prior Month 113 551
200 Day MA 14.66 USD
Short Ratio 2.27
Shares Short 111 513
Short Percent 2.84 %

Dynamics of changes in the value of assets

N

NBST

10.88 USD Newbury Street Acquisition Corp 0 (0%)
Detailed analytics
O

OPXS

7.90 USD Optex Systems Holdings Inc. Common Stock -0.15 (-1.86%)
Detailed analytics
0

0328

4.12 HKD Alco Holdings Ltd -0.04 (-6.36%)
Detailed analytics
3

3398

0.20 HKD China Ting Group Holdings Ltd +0 (+0%)
Detailed analytics
P

PRMMF

0.0012 USD Premier African Minerals Limited 0 (0%)
Detailed analytics